TISIDB

Summary
Symbol	POLB
Name	polymerase (DNA directed), beta
Aliases	DNA pol beta; DNA polymerase beta subunit; DNA polymerase beta
Chromosomal Location	8p12-p11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus. Cytoplasm. Note=Cytoplasmic in normal conditions. Translocates to the nucleus following DNA damage.
Domain	PF14792 DNA polymerase beta palm PF14791 DNA polymerase beta thumb PF10391 Fingers domain of DNA polymerase lambda PF14716 Helix-hairpin-helix domain
Function	Repair polymerase that plays a key role in base-excision repair. Has 5'-deoxyribose-5-phosphate lyase (dRP lyase) activity that removes the 5' sugar phosphate and also acts as a DNA polymerase that adds one nucleotide to the 3' end of the arising single-nucleotide gap. Conducts 'gap-filling' DNA synthesis in a stepwise distributive fashion rather than in a processive fashion as for other DNA polymerases.

> Gene Ontology [ TOP ]
Biological Process	GO:0002200 somatic diversification of immune receptors GO:0002377 immunoglobulin production GO:0002440 production of molecular mediator of immune response GO:0002562 somatic diversification of immune receptors via germline recombination within a single locus GO:0002566 somatic diversification of immune receptors via somatic mutation GO:0006260 DNA replication GO:0006261 DNA-dependent DNA replication GO:0006266 DNA ligation GO:0006284 base-excision repair GO:0006286 base-excision repair, base-free sugar-phosphate removal GO:0006287 base-excision repair, gap-filling GO:0006288 base-excision repair, DNA ligation GO:0006290 pyrimidine dimer repair GO:0006310 DNA recombination GO:0007431 salivary gland development GO:0007435 salivary gland morphogenesis GO:0007568 aging GO:0008630 intrinsic apoptotic signaling pathway in response to DNA damage GO:0009314 response to radiation GO:0010212 response to ionizing radiation GO:0010332 response to gamma radiation GO:0016311 dephosphorylation GO:0016444 somatic cell DNA recombination GO:0016445 somatic diversification of immunoglobulins GO:0016446 somatic hypermutation of immunoglobulin genes GO:0016447 somatic recombination of immunoglobulin gene segments GO:0022612 gland morphogenesis GO:0033151 V(D)J recombination GO:0033152 immunoglobulin V(D)J recombination GO:0035272 exocrine system development GO:0036296 response to increased oxygen levels GO:0045471 response to ethanol GO:0048535 lymph node development GO:0048536 spleen development GO:0048732 gland development GO:0048872 homeostasis of number of cells GO:0051103 DNA ligation involved in DNA repair GO:0051402 neuron apoptotic process GO:0055093 response to hyperoxia GO:0070482 response to oxygen levels GO:0070997 neuron death GO:0071707 immunoglobulin heavy chain V-D-J recombination GO:0071897 DNA biosynthetic process GO:0097193 intrinsic apoptotic signaling pathway GO:0097305 response to alcohol GO:0098501 polynucleotide dephosphorylation GO:0098502 DNA dephosphorylation
Molecular Function	GO:0003684 damaged DNA binding GO:0003887 DNA-directed DNA polymerase activity GO:0003906 DNA-(apurinic or apyrimidinic site) lyase activity GO:0004518 nuclease activity GO:0004519 endonuclease activity GO:0004520 endodeoxyribonuclease activity GO:0004536 deoxyribonuclease activity GO:0008017 microtubule binding GO:0015631 tubulin binding GO:0016779 nucleotidyltransferase activity GO:0016829 lyase activity GO:0016835 carbon-oxygen lyase activity GO:0034061 DNA polymerase activity
Cellular Component	GO:0005819 spindle GO:0005874 microtubule GO:0005876 spindle microtubule

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa03410 Base excision repair
Reactome	R-HSA-5649702: APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway R-HSA-73930: Abasic sugar-phosphate removal via the single-nucleotide replacement pathway R-HSA-73884: Base Excision Repair R-HSA-73894: DNA Repair R-HSA-5688426: Deubiquitination R-HSA-392499: Metabolism of proteins R-HSA-5651801: PCNA-Dependent Long Patch Base Excision Repair R-HSA-110362: POLB-Dependent Long Patch Base Excision Repair R-HSA-597592: Post-translational protein modification R-HSA-110373: Resolution of AP sites via the multiple-nucleotide patch replacement pathway R-HSA-110381: Resolution of AP sites via the single-nucleotide replacement pathway R-HSA-73933: Resolution of Abasic Sites (AP sites) R-HSA-5689880: Ub-specific processing proteases

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa03410 Base excision repair

Reactome

R-HSA-5649702: APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway
R-HSA-73930: Abasic sugar-phosphate removal via the single-nucleotide replacement pathway
R-HSA-73884: Base Excision Repair
R-HSA-73894: DNA Repair
R-HSA-5688426: Deubiquitination
R-HSA-392499: Metabolism of proteins
R-HSA-5651801: PCNA-Dependent Long Patch Base Excision Repair
R-HSA-110362: POLB-Dependent Long Patch Base Excision Repair
R-HSA-597592: Post-translational protein modification
R-HSA-110373: Resolution of AP sites via the multiple-nucleotide patch replacement pathway
R-HSA-110381: Resolution of AP sites via the single-nucleotide replacement pathway
R-HSA-73933: Resolution of Abasic Sites (AP sites)
R-HSA-5689880: Ub-specific processing proteases

Summary
Symbol	POLB
Name	polymerase (DNA directed), beta
Aliases	DNA pol beta; DNA polymerase beta subunit; DNA polymerase beta
Chromosomal Location	8p12-p11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between POLB and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	POLB
Name	polymerase (DNA directed), beta
Aliases	DNA pol beta; DNA polymerase beta subunit; DNA polymerase beta
Chromosomal Location	8p12-p11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of POLB in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	POLB
Name	polymerase (DNA directed), beta
Aliases	DNA pol beta; DNA polymerase beta subunit; DNA polymerase beta
Chromosomal Location	8p12-p11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of POLB in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.669	0.0213
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.399	0.846
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.866	0.57
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.266	0.454
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.049	0.974
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.661	0.729
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.051	0.894
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.255	0.862
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.17	0.917
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.103	0.936
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.169	0.931
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.118	0.237

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of POLB in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	1.4	-1.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	7.1	-7.1	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	POLB
Name	polymerase (DNA directed), beta
Aliases	DNA pol beta; DNA polymerase beta subunit; DNA polymerase beta
Chromosomal Location	8p12-p11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of POLB. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	POLB
Name	polymerase (DNA directed), beta
Aliases	DNA pol beta; DNA polymerase beta subunit; DNA polymerase beta
Chromosomal Location	8p12-p11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of POLB. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by POLB. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	POLB
Name	polymerase (DNA directed), beta
Aliases	DNA pol beta; DNA polymerase beta subunit; DNA polymerase beta
Chromosomal Location	8p12-p11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of POLB. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	POLB
Name	polymerase (DNA directed), beta
Aliases	DNA pol beta; DNA polymerase beta subunit; DNA polymerase beta
Chromosomal Location	8p12-p11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of POLB expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	POLB
Name	polymerase (DNA directed), beta
Aliases	DNA pol beta; DNA polymerase beta subunit; DNA polymerase beta
Chromosomal Location	8p12-p11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between POLB and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	POLB
Name	polymerase (DNA directed), beta
Aliases	DNA pol beta; DNA polymerase beta subunit; DNA polymerase beta
Chromosomal Location	8p12-p11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting POLB collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting POLB.

ID	Name	Drug Type	Targets	#Targets
DB00987	Cytarabine	Small Molecule	POLB	1
DB01592	Iron	Small Molecule	AHSP, CP, EGLN1, FEN1, FTH1, FXN, HBA1, HDAC8, NEIL1, NEIL2, POLB, ......	13
DB03222	dATP	Small Molecule	POLB	1
DB07479	(1S)-1,2,3,4-TETRAHYDRO-BENZO[C]PHENANTHRENE-2,3,4-TRIOL	Small Molecule	POLB	1

Browse POLB